Hiperparatiroidismo secundario insuficiencia renal
Kidney diseases represent a major global health problem. Secondary hyperparathyroidism appears more frequently in advanced chronic renal failure when the decrease in the synthesis of active vitamin D in the kidneys and factors produce hypocalcemia and stimulate the secretion of parathyroid hormone (...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artículo |
| Idioma: | Castellano |
| Publicado: |
2020
|
| Materias: | |
| Acceso en línea: | https://dialnet.unirioja.es/servlet/oaiart?codigo=7983624 |
| Fuente: | RECIMUNDO: Revista Científica de la Investigación y el Conocimiento, ISSN 2588-073X, Vol. 4, Nº. 4, 2020, pags. 282-290 |
| Etiquetas: |
Añadir etiqueta
Sin etiquetas: Sea el primero en etiquetar este registro
|
| Sumario: |
Kidney diseases represent a major global health problem. Secondary hyperparathyroidism appears more frequently in advanced chronic renal failure when the decrease in the synthesis of active vitamin D in the kidneys and factors produce hypocalcemia and stimulate the secretion of parathyroid hormone (PTH) in a chronic form. About 10% of the world's pop-ulation suffers from chronic kidney failure. And it is estimated that of this total, between 10 and 20% present secondary hyperparathyroidism, and 5% of this total present it in a severe form. It is important to emphasize that the complications of renal failure carry a high risk of mortality and that the presence of secondary hyperparathyroidism increases this risk. The general objective of this study is to summarize some generalities of secondary hyperparathyroidism in renal failure, with special emphasis on the treatment of this important pathology. The research design is bibliographic, and the methodology is review. The treatment of secondary hyperparathyroidism is mainly medical (Calcimetics), with surgical management only those patient’s refractory to treatment and with complications derived from excess PTH. It is essential for the management and monitoring of this pathology, to control the serum values of each of the parameters, together with the control of calcium. Likewise, it must be ensured that the therapeutic measures taken are reasonable in maintaining calcium and phosphorus levels within normal parameters. Finally, it is important to consider that the goals in the treatment of secondary hyperpara-thyroidism are adapted and individualized to each individual patient and their clinical setting. |
|---|